Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Meeting Report: 2022 Muscular Dystrophy Association Summit on ‘Safety and Challenges in Gene Transfer Therapy’

14 Feb 2023

Abstract excerpt

Muscular Dystrophy Association (MDA) has invested over $125M in the development of gene therapy for neuromuscular disorders (NMD) over the past 20 years. As a lead initiator of progress in this important field of medicine and to help ensure continued progress towards therapies for patients, MDA organized a dedicated summit in January 2022 to address emerging challenges in safely delivering adeno-associated virus...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Muscle Physiology and Disorders
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36806515
DOI: 10.3233/jnd-221639

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Meeting Report: 2022 Muscular Dystrophy Association Summit on ‘Safety and Challenges in Gene Transfer Therapy’PMID 36806515Read ↗

Meeting Report: 2023 Muscular Dystrophy Association Summit on ‘Safety and Challenges in Gene Therapy of Neuromuscular Diseases’Semantic proximity Read ↗

Current and Emerging Therapeutic Strategies for the Treatment of Duchenne Muscular Dystrophy.Semantic proximity Read ↗

Treating neuromuscular diseases: unveiling gene therapy breakthroughs and pioneering future applicationsSemantic proximity Read ↗

Muscular dystrophy: new challenges and review of the current clinical trials.Semantic proximity Read ↗

Consensus recommendations and considerations for the delivery and monitoring of gene therapy in patients with Duchenne muscular dystrophySemantic proximity Read ↗

Towards a Cure: Emerging Therapeutic Advances for DMD, LGMD, and GNEM- Insights from Pre-Clinical and Clinical ResearchSemantic proximity Read ↗

AAV microdystrophin gene replacement therapy for Duchenne muscular dystrophy: progress and prospectsSemantic proximity Read ↗

Analysis of the adverse effects of used clinical Antisense Oligonucleotide drugs in DMD patients based on the FAERS databaseSemantic proximity Read ↗

Progress and prospects of gene therapy clinical trials for the muscular dystrophiesSemantic proximity Read ↗

Food and Drug Administration Lifts Clinical Hold on Pfizer Duchenne Muscular Dystrophy Gene Therapy Linked to Patient DeathSemantic proximity Read ↗

Of rAAV and Men: From Genetic Neuromuscular Disorder Efficacy and Toxicity Preclinical Studies to Clinical Trials and BackSemantic proximity Read ↗

Novel Muscle-Tropic AAV Capsids with Dramatically Enhanced Transduction and Safety Profiles in Non-Human PrimatesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.